Uroplasty/Empi
This article was originally published in The Gray Sheet
Executive Summary
Letter of intent is signed under which urinary incontinence treatment firm Uroplasty will purchase Empi's Clinical EMG System for $400,000. The product is a biofeedback device used to treat UI. Closing of the deal is subject to certain conditions, including the negotiation and execution of a definitive agreement and Uroplasty's due diligence review of "certain software" related to the system, according to Minneapolis-based Uroplasty, which is developing the Macroplastique injectable treatment for female stress UI